Targets › IL23
1 program from 1 company in 1 trial: 1 Phase 1; Immunology.
Open in Phaseline: the race on IL23, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University Medical Center Groningen | Risankizumab-800CW Anti-IL-23 p19 monoclonal antibody (fluorescently labeled) | IL23 | Phase 1 | Ulcerative Colitis (UC) | – |
Ulcerative Colitis (UC) (1)
antibody (1)
University Medical Center Groningen (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.